Erythropoietin and Early Iron Supplement and Retinopathy of Prematurity

Sheba Medical Center400 enrolled

Overview

To evaluate the possibility that erythropoietin with early iron supplementation may induce retinopathy of prematurity or worsen this disease. In addition risk factors for the development of ROP will be checked.

Study Type

OBSERVATIONAL

Enrollment

400

Conditions

Retinopathy of Prematurity

Interventions

erythropoietin and early iron supplementsDRUG

Eligibility

Sex: ALLMin age: 2 WeeksMax age: 3 Months

Medical Language ↔ Plain English

Inclusion Criteria: * all premature infants with birth weight of 1250 grams or less Exclusion Criteria: * none

Locations (1)

Neonatal Department, Sheba Medical Center

Ramat Gan, Israel

RECRUITING

Central Contacts

Jacob Kuint, MD

CONTACT

972-3-5303030 kuint-j@sheba.health.gov.il

Irit Eisen, MD

CONTACT

972-3-5303030

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.